Drug-drug interactions with raltegravir

about

Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Integrase inhibitors: why do we need a new drug class for HIV therapy?Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients.

P2860

Q33585344-CC8C339B-7998-47BC-8E7F-F76092663BE7 Q36452175-D2464815-D243-463C-A915-755319DB8506 Q49228013-0E55F39B-842D-41C4-A95D-D85D2679D30B

P2860

Drug-drug interactions with raltegravir

Item

http://www.wikidata.org/entity/Q37644118

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Drug-drug interactions with raltegravir

@en

Drug-drug interactions with raltegravir.

@nl

type

Item

label

Drug-drug interactions with raltegravir

@en

Drug-drug interactions with raltegravir.

@nl

prefLabel

Drug-drug interactions with raltegravir

@en

Drug-drug interactions with raltegravir.

@nl

P1476

Drug-drug interactions with raltegravir

@en

P2093

David M Burger

http://www.w3.org/2001/XMLSchema#string

P2860

Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort

Lack of a significant drug interaction between raltegravir and tenofovir.

Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.

Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.

Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

P304

17-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P407

English

P478

14 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2009-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19959412

http://www.w3.org/2001/XMLSchema#string

P921

human immunodeficiency virus infectious disease

Retroviridae infectious disease

mechanism of action

P932

3516822

http://www.w3.org/2001/XMLSchema#string

Drug-drug interactions with raltegravir

about

P2860

P2860

Drug-drug interactions with raltegravir

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P407

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P407

P478

P577

P698

P921

P932